ISSX 27th North American Meeting

Why is DMPK important during drug development?

Drug metabolism and pharmacokinetics (DMPK) studies provide critical insights into how a therapeutic is absorbed, distributed, metabolized, and eliminated. These data help sponsors optimize candidate selection, understand exposure, inform dose selection, evaluate safety, and support confident decision-making during early drug development.

Can BioAgilytix support pharmacokinetic studies across multiple therapeutic modalities?

Yes. BioAgilytix supports pharmacokinetic programs for a broad range of therapeutic modalities, including small molecules, biologics, peptides, oligonucleotides, antibody-drug conjugates (ADCs), cell and gene therapies, and other emerging therapeutics. Our scientists develop fit-for-purpose analytical strategies tailored to the unique characteristics of each program.

How does LC-MS support DMPK programs?

LC-MS provides highly sensitive and selective quantitative analysis for pharmacokinetic studies, metabolite identification, and drug characterization. Depending on your program's objectives, LC-MS can be used independently or alongside ligand binding assays to generate complementary data that supports informed development decisions.

When should biomarkers be incorporated into a DMPK program?

Biomarkers are most valuable when integrated early in development. They can provide important insights into pharmacodynamic activity, target engagement, biological response, and treatment effects, helping sponsors better understand therapeutic performance throughout early drug development.

Can BioAgilytix support studies from discovery through clinical development?

Yes. BioAgilytix provides integrated bioanalytical support across discovery, preclinical, and clinical development. Our scientific teams work closely with sponsors to develop, validate, and implement analytical strategies that evolve alongside each program while maintaining regulatory and scientific rigor.

What bioanalytical capabilities does BioAgilytix offer for DMPK programs?

BioAgilytix offers integrated bioanalytical capabilities including pharmacokinetics, LC-MS bioanalysis, ligand binding assays, biomarkers, metabolite characterization, immunogenicity, and method development and validation. Our scientists tailor analytical strategies to support the specific objectives of each development program.